Kadmon Holdings, Inc.: Announced pos. primary analysis results (May 2020) in pivotal trial of ROCK inhibitor-KD025 (Belumosudil) in cGVHD pts receiving 2+ prior therapy lines; ORRs of 73% and 74% in 200mg QD and 200mg BID arms, respectively. Belumosudil is being reviewed under Real-Time Oncology Review (RTOR) Pilot Program by the FDA; NDA submission exp Q4 2020. Enrolling pts in Ph 2 trial (sys. sclerosis).
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Fibrosis, Immunotherapy, Oncology
Industry
Biotechnology, Pharmaceuticals
Listing
Public, USA
Market Cap
500MM - 1B
Website:
Profiles:
Address:
450 East 29th Street
New York, NY 10016
United States

Company Participants at Solebury Trout CEO & Investor Ski Conference 2020

  • Ellen Cavaleri, Director, Investor Relations
  • Harlan W. Waksal, MD, President and CEO
  • Steve Meehan, CFO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Lead Programs

KD025

Indication Phase
Chronic Graft-Versus-Host Disease 2
Systemic Sclerosis 2
Idiopathic Pulmonary Fibrosis 2

KD034

Indication Phase
Wilson’s Disease 3

Top 10 Holders of Kadmon Holdings Inc Warrant 2017-28.09.22 On Kadmon Hldngs

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
The Vanguard Group, Inc. 0.00 0 0.00 Funds 2020-05-31

Top 10 Holders of Kadmon Holdings, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Perceptive Advisors LLC 12.13 15,711,334 73.84 13F 2020-03-31
Consonance Capital Management LP 12.06 15,608,948 73.36 13F 2020-03-31
Vivo Capital LLC 9.68 12,539,515 58.94 13F 2020-03-31
Third Point LLC 7.27 9,407,745 44.22 13F 2020-03-31
The Vanguard Group, Inc. 6.27 8,114,440 38.14 Funds 2020-05-31
Vanguard Group, Inc. (Subfiler) 6.04 7,826,873 36.79 13F 2020-03-31
Boxer Capital LLC 4.79 6,205,882 29.17 13F 2020-03-31
Citadel LP 4.55 5,891,517 27.69 13F 2020-03-31
BlackRock Fund Advisors 4.29 5,554,287 26.11 13F 2020-03-31
T. Rowe Price Associates, Inc. (Investment Management) 4.27 5,527,706 25.98 13F 2020-03-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.